| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 53 | 2023 | 1912 | 3.470 |
Why?
|
| Mycobacterium tuberculosis | 80 | 2020 | 1832 | 3.310 |
Why?
|
| Mycobacterium leprae | 45 | 2021 | 94 | 3.070 |
Why?
|
| Leprosy | 45 | 2019 | 124 | 2.760 |
Why?
|
| BCG Vaccine | 33 | 2018 | 369 | 1.680 |
Why?
|
| Immunization Programs | 4 | 2022 | 260 | 1.480 |
Why?
|
| Macrophages | 72 | 2022 | 5660 | 1.380 |
Why?
|
| Bacterial Vaccines | 18 | 2014 | 403 | 1.220 |
Why?
|
| Tuberculosis Vaccines | 7 | 2020 | 50 | 1.170 |
Why?
|
| Mycobacterium | 28 | 1999 | 249 | 1.140 |
Why?
|
| International Cooperation | 8 | 2020 | 1420 | 1.100 |
Why?
|
| World Health Organization | 10 | 2020 | 1318 | 1.090 |
Why?
|
| Vaccines | 9 | 2023 | 823 | 1.040 |
Why?
|
| Tuberculosis, Pulmonary | 15 | 2019 | 810 | 1.020 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 4 | 2017 | 113 | 1.000 |
Why?
|
| Antigens, Bacterial | 33 | 2019 | 1172 | 1.000 |
Why?
|
| Mycobacterium bovis | 24 | 2009 | 150 | 0.990 |
Why?
|
| Nuclear Weapons | 1 | 2024 | 13 | 0.950 |
Why?
|
| Disease Outbreaks | 8 | 2019 | 1771 | 0.950 |
Why?
|
| Nuclear Warfare | 1 | 2023 | 31 | 0.940 |
Why?
|
| Bombs | 1 | 2023 | 72 | 0.910 |
Why?
|
| Vaccination | 11 | 2022 | 3279 | 0.910 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2024 | 547 | 0.880 |
Why?
|
| Containment of Biohazards | 3 | 2012 | 37 | 0.870 |
Why?
|
| Interferon-gamma | 34 | 2023 | 3207 | 0.850 |
Why?
|
| Social Control, Informal | 1 | 2022 | 46 | 0.820 |
Why?
|
| Leprosy, Lepromatous | 10 | 2021 | 23 | 0.820 |
Why?
|
| Public Policy | 3 | 2022 | 572 | 0.760 |
Why?
|
| Antitubercular Agents | 6 | 2020 | 1320 | 0.740 |
Why?
|
| Leprosy, Tuberculoid | 8 | 2021 | 15 | 0.740 |
Why?
|
| Public Health | 8 | 2022 | 2602 | 0.720 |
Why?
|
| Neglected Diseases | 2 | 2018 | 64 | 0.720 |
Why?
|
| Pertussis Vaccine | 4 | 2017 | 34 | 0.670 |
Why?
|
| Vaccines, Synthetic | 13 | 1997 | 634 | 0.610 |
Why?
|
| Health Education | 3 | 2022 | 1056 | 0.600 |
Why?
|
| Communicable Disease Control | 3 | 2020 | 857 | 0.600 |
Why?
|
| Whooping Cough | 1 | 2017 | 82 | 0.570 |
Why?
|
| T-Lymphocytes | 51 | 2021 | 10183 | 0.560 |
Why?
|
| Research | 8 | 2019 | 1999 | 0.530 |
Why?
|
| Financing, Government | 8 | 2012 | 468 | 0.520 |
Why?
|
| Epidemics | 2 | 2018 | 523 | 0.510 |
Why?
|
| Bacterial Proteins | 23 | 2009 | 3854 | 0.500 |
Why?
|
| Leprostatic Agents | 1 | 2014 | 14 | 0.500 |
Why?
|
| Influenza in Birds | 2 | 2012 | 75 | 0.500 |
Why?
|
| Genes, Bacterial | 20 | 2005 | 1079 | 0.490 |
Why?
|
| Internationality | 3 | 2016 | 1002 | 0.490 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2017 | 248 | 0.470 |
Why?
|
| Vaccines, DNA | 4 | 2018 | 305 | 0.470 |
Why?
|
| Malaria | 5 | 2012 | 1239 | 0.450 |
Why?
|
| Hypersensitivity, Delayed | 28 | 2008 | 484 | 0.450 |
Why?
|
| Developing Countries | 16 | 2007 | 2815 | 0.440 |
Why?
|
| Tuberculin Test | 13 | 2020 | 214 | 0.440 |
Why?
|
| Phagosomes | 5 | 2019 | 193 | 0.430 |
Why?
|
| Immunity, Cellular | 33 | 2018 | 1607 | 0.420 |
Why?
|
| Influenza, Human | 3 | 2012 | 1479 | 0.420 |
Why?
|
| Interleukin-12 | 6 | 2018 | 580 | 0.410 |
Why?
|
| Health Priorities | 5 | 2019 | 380 | 0.390 |
Why?
|
| Plasmids | 20 | 2008 | 2308 | 0.390 |
Why?
|
| Safety | 5 | 2012 | 1186 | 0.380 |
Why?
|
| Treatment Refusal | 1 | 2014 | 421 | 0.380 |
Why?
|
| Measles Vaccine | 3 | 2019 | 76 | 0.370 |
Why?
|
| Influenza A virus | 2 | 2012 | 456 | 0.360 |
Why?
|
| DNA, Bacterial | 12 | 1996 | 1465 | 0.360 |
Why?
|
| Lymphocyte Activation | 37 | 2019 | 5524 | 0.360 |
Why?
|
| Humans | 219 | 2024 | 744376 | 0.360 |
Why?
|
| Interleukins | 4 | 2019 | 791 | 0.350 |
Why?
|
| International Agencies | 1 | 2010 | 240 | 0.350 |
Why?
|
| Host-Pathogen Interactions | 3 | 2021 | 1480 | 0.340 |
Why?
|
| Lymphokines | 11 | 1995 | 949 | 0.340 |
Why?
|
| Molecular Biology | 2 | 2012 | 596 | 0.340 |
Why?
|
| AIDS Vaccines | 5 | 2001 | 938 | 0.340 |
Why?
|
| Histocompatibility Antigens Class I | 5 | 2000 | 1366 | 0.340 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 9 | 1997 | 343 | 0.330 |
Why?
|
| Mice, Inbred BALB C | 26 | 2009 | 6387 | 0.330 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2001 | 187 | 0.330 |
Why?
|
| Antigen Presentation | 8 | 2019 | 1284 | 0.320 |
Why?
|
| Lymphocytes | 34 | 1984 | 2617 | 0.320 |
Why?
|
| Animals | 164 | 2017 | 168770 | 0.320 |
Why?
|
| Immune Tolerance | 20 | 2004 | 2259 | 0.310 |
Why?
|
| T-Lymphocytes, Regulatory | 17 | 1992 | 2988 | 0.310 |
Why?
|
| T-Lymphocytes, Cytotoxic | 8 | 2018 | 1821 | 0.310 |
Why?
|
| Major Histocompatibility Complex | 5 | 1998 | 936 | 0.300 |
Why?
|
| Nitric Oxide | 9 | 2023 | 2132 | 0.300 |
Why?
|
| Virulence | 14 | 2005 | 1333 | 0.300 |
Why?
|
| Genetic Engineering | 2 | 2012 | 951 | 0.290 |
Why?
|
| Guinea Pigs | 36 | 2011 | 1386 | 0.290 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 11 | 2018 | 906 | 0.290 |
Why?
|
| T-Lymphocyte Subsets | 11 | 2016 | 1837 | 0.290 |
Why?
|
| Vesicular stomatitis Indiana virus | 16 | 1989 | 94 | 0.290 |
Why?
|
| History, 20th Century | 4 | 2020 | 2740 | 0.280 |
Why?
|
| RNA, Bacterial | 2 | 2019 | 390 | 0.280 |
Why?
|
| Immunity, Innate | 15 | 2019 | 2962 | 0.280 |
Why?
|
| Glycolipids | 3 | 2017 | 204 | 0.280 |
Why?
|
| Pandemics | 4 | 2020 | 8386 | 0.270 |
Why?
|
| Mice | 98 | 2017 | 81202 | 0.270 |
Why?
|
| Measles virus | 5 | 1997 | 68 | 0.270 |
Why?
|
| Leucine | 11 | 2011 | 560 | 0.270 |
Why?
|
| Vaccines, Attenuated | 7 | 2017 | 342 | 0.270 |
Why?
|
| Antimalarials | 1 | 2012 | 905 | 0.270 |
Why?
|
| Mycobacteriophages | 7 | 1997 | 19 | 0.260 |
Why?
|
| Conservation of Natural Resources | 1 | 2007 | 204 | 0.260 |
Why?
|
| Directly Observed Therapy | 1 | 2005 | 137 | 0.260 |
Why?
|
| Cytotoxicity, Immunologic | 14 | 2000 | 1369 | 0.260 |
Why?
|
| Hydro-Lyases | 2 | 2006 | 94 | 0.250 |
Why?
|
| Bioterrorism | 2 | 2005 | 143 | 0.250 |
Why?
|
| Drug Costs | 1 | 2012 | 1105 | 0.250 |
Why?
|
| Drug Resistance, Microbial | 7 | 1999 | 862 | 0.250 |
Why?
|
| Cell Line | 42 | 2004 | 16000 | 0.240 |
Why?
|
| Biomedical Research | 4 | 2012 | 3309 | 0.240 |
Why?
|
| Interleukin-4 | 9 | 2000 | 1147 | 0.240 |
Why?
|
| United States | 25 | 2020 | 69869 | 0.230 |
Why?
|
| Clone Cells | 22 | 1997 | 1692 | 0.230 |
Why?
|
| Child Health Services | 4 | 1997 | 667 | 0.230 |
Why?
|
| Evolution, Molecular | 1 | 2012 | 1939 | 0.230 |
Why?
|
| Ethics, Medical | 2 | 1999 | 792 | 0.220 |
Why?
|
| Sigma Factor | 2 | 2002 | 175 | 0.220 |
Why?
|
| Human Experimentation | 2 | 2001 | 127 | 0.220 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3242 | 0.220 |
Why?
|
| Squalene | 1 | 2022 | 32 | 0.220 |
Why?
|
| Lipopolysaccharides | 8 | 2016 | 2216 | 0.220 |
Why?
|
| Superoxides | 6 | 1991 | 387 | 0.220 |
Why?
|
| DNA Transposable Elements | 8 | 2017 | 748 | 0.220 |
Why?
|
| Antigens | 17 | 1997 | 1466 | 0.210 |
Why?
|
| Th17 Cells | 2 | 2019 | 766 | 0.210 |
Why?
|
| Interferons | 9 | 1983 | 706 | 0.210 |
Why?
|
| Tuberculin | 21 | 2008 | 66 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 39 | 2008 | 21833 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3135 | 0.210 |
Why?
|
| Cytokines | 18 | 2019 | 7323 | 0.210 |
Why?
|
| Hemiterpenes | 3 | 1997 | 18 | 0.210 |
Why?
|
| History, 17th Century | 2 | 2020 | 111 | 0.210 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 137 | 0.210 |
Why?
|
| Isoniazid | 3 | 1998 | 274 | 0.200 |
Why?
|
| Antigens, Viral | 5 | 2012 | 1035 | 0.200 |
Why?
|
| History, Ancient | 2 | 2020 | 212 | 0.200 |
Why?
|
| Federal Government | 2 | 2019 | 260 | 0.200 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 7 | 1980 | 108 | 0.200 |
Why?
|
| Phagocytosis | 13 | 2006 | 1539 | 0.200 |
Why?
|
| Parents | 2 | 2019 | 3405 | 0.200 |
Why?
|
| Developed Countries | 3 | 2000 | 437 | 0.200 |
Why?
|
| History, 21st Century | 2 | 2020 | 1534 | 0.200 |
Why?
|
| Financial Support | 2 | 2017 | 115 | 0.200 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 6 | 1998 | 834 | 0.190 |
Why?
|
| Acquired Immunodeficiency Syndrome | 6 | 2010 | 2232 | 0.190 |
Why?
|
| Delivery of Health Care | 5 | 2017 | 5321 | 0.190 |
Why?
|
| Tobacco Industry | 1 | 2022 | 126 | 0.190 |
Why?
|
| Gene Expression Regulation, Bacterial | 4 | 2009 | 1122 | 0.190 |
Why?
|
| Human Genome Project | 1 | 2001 | 193 | 0.190 |
Why?
|
| Protein Kinases | 5 | 2003 | 1640 | 0.190 |
Why?
|
| Organophosphorus Compounds | 3 | 1997 | 215 | 0.190 |
Why?
|
| Immunotherapy | 6 | 2014 | 4445 | 0.190 |
Why?
|
| Isomerases | 1 | 2000 | 56 | 0.190 |
Why?
|
| History, Medieval | 1 | 2020 | 63 | 0.180 |
Why?
|
| Measles | 3 | 1997 | 168 | 0.180 |
Why?
|
| Genetic Vectors | 14 | 2005 | 3424 | 0.180 |
Why?
|
| Amino Acid Oxidoreductases | 3 | 1995 | 151 | 0.180 |
Why?
|
| Monocytes | 9 | 2019 | 2596 | 0.180 |
Why?
|
| Malaria Vaccines | 2 | 2001 | 158 | 0.180 |
Why?
|
| Spleen | 20 | 2008 | 2362 | 0.180 |
Why?
|
| Morbidity | 3 | 1998 | 1768 | 0.180 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2002 | 371 | 0.180 |
Why?
|
| History, 18th Century | 1 | 2020 | 213 | 0.170 |
Why?
|
| Antigens, Surface | 6 | 1998 | 1663 | 0.170 |
Why?
|
| History, 19th Century | 2 | 2020 | 720 | 0.170 |
Why?
|
| Japan | 1 | 2023 | 1360 | 0.170 |
Why?
|
| Genomic Library | 2 | 1998 | 193 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 3922 | 0.170 |
Why?
|
| Ethics, Research | 1 | 2001 | 191 | 0.170 |
Why?
|
| Emigration and Immigration | 1 | 2002 | 402 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2009 | 3921 | 0.160 |
Why?
|
| Antimicrobial Cationic Peptides | 5 | 2019 | 362 | 0.160 |
Why?
|
| Smallpox Vaccine | 1 | 2019 | 80 | 0.160 |
Why?
|
| Genome, Bacterial | 3 | 2005 | 760 | 0.160 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2020 | 657 | 0.160 |
Why?
|
| Molecular Sequence Data | 32 | 2009 | 18111 | 0.160 |
Why?
|
| Langerhans Cells | 1 | 2019 | 173 | 0.160 |
Why?
|
| RNA, Messenger | 17 | 2019 | 13035 | 0.160 |
Why?
|
| Health Policy | 5 | 2019 | 2661 | 0.160 |
Why?
|
| beta 2-Microglobulin | 3 | 1994 | 315 | 0.160 |
Why?
|
| Killer Cells, Natural | 8 | 1987 | 2133 | 0.160 |
Why?
|
| Genetics, Medical | 1 | 2001 | 338 | 0.160 |
Why?
|
| Receptors, Purinergic P2 | 1 | 1999 | 153 | 0.160 |
Why?
|
| Interferon Type I | 5 | 2019 | 542 | 0.160 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1998 | 43 | 0.160 |
Why?
|
| Shigella flexneri | 1 | 1999 | 132 | 0.150 |
Why?
|
| Drug Industry | 2 | 2022 | 746 | 0.150 |
Why?
|
| Acne Vulgaris | 1 | 2022 | 302 | 0.150 |
Why?
|
| Gene Expression Profiling | 7 | 2021 | 9445 | 0.150 |
Why?
|
| Epidemiology | 1 | 2020 | 287 | 0.150 |
Why?
|
| Membrane Glycoproteins | 10 | 2022 | 3771 | 0.150 |
Why?
|
| Macrophage Activation | 7 | 2001 | 560 | 0.150 |
Why?
|
| Budgets | 3 | 2010 | 229 | 0.150 |
Why?
|
| Leishmaniasis | 5 | 1989 | 47 | 0.140 |
Why?
|
| Mutagenesis, Insertional | 7 | 2017 | 655 | 0.140 |
Why?
|
| Guanidines | 3 | 1995 | 193 | 0.140 |
Why?
|
| Cells, Cultured | 33 | 2019 | 19233 | 0.140 |
Why?
|
| Base Sequence | 20 | 2005 | 12797 | 0.140 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2017 | 90 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2020 | 1035 | 0.140 |
Why?
|
| Research Support as Topic | 3 | 2005 | 705 | 0.140 |
Why?
|
| Child Welfare | 2 | 2005 | 523 | 0.140 |
Why?
|
| Virus Replication | 11 | 2023 | 2535 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 841 | 0.140 |
Why?
|
| H-2 Antigens | 4 | 1992 | 366 | 0.140 |
Why?
|
| Venezuela | 3 | 2014 | 73 | 0.140 |
Why?
|
| Bacterial Toxins | 2 | 1999 | 931 | 0.140 |
Why?
|
| Th2 Cells | 3 | 1999 | 1061 | 0.140 |
Why?
|
| Demyelinating Diseases | 9 | 2017 | 354 | 0.140 |
Why?
|
| Ferrets | 2 | 2017 | 194 | 0.140 |
Why?
|
| Chronic Disease | 3 | 2005 | 9145 | 0.140 |
Why?
|
| Cloning, Molecular | 13 | 1995 | 4320 | 0.140 |
Why?
|
| Autophagy | 3 | 2019 | 1297 | 0.130 |
Why?
|
| Dendritic Cells | 4 | 2006 | 2725 | 0.130 |
Why?
|
| Birds | 3 | 2012 | 163 | 0.130 |
Why?
|
| Mycoplasma | 1 | 1995 | 139 | 0.130 |
Why?
|
| RNA, Transfer | 1 | 2018 | 316 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 12 | 1998 | 9274 | 0.130 |
Why?
|
| Haemophilus influenzae | 1 | 1995 | 172 | 0.130 |
Why?
|
| Cation Transport Proteins | 1 | 1998 | 327 | 0.130 |
Why?
|
| Mice, Inbred Strains | 6 | 1997 | 1828 | 0.130 |
Why?
|
| Viral Core Proteins | 1 | 1995 | 162 | 0.130 |
Why?
|
| Lung | 16 | 2009 | 9857 | 0.130 |
Why?
|
| Nitric Oxide Synthase | 6 | 2001 | 915 | 0.130 |
Why?
|
| Granuloma | 8 | 1999 | 319 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2004 | 4424 | 0.130 |
Why?
|
| Arginine | 3 | 1995 | 944 | 0.130 |
Why?
|
| Antigens, Protozoan | 1 | 1997 | 322 | 0.130 |
Why?
|
| Geography | 1 | 2017 | 669 | 0.130 |
Why?
|
| Amino Acid Sequence | 19 | 2009 | 13814 | 0.130 |
Why?
|
| Intracellular Fluid | 3 | 2006 | 203 | 0.120 |
Why?
|
| United States Public Health Service | 1 | 1994 | 31 | 0.120 |
Why?
|
| Cost of Illness | 3 | 2019 | 1860 | 0.120 |
Why?
|
| Lepromin | 6 | 1986 | 8 | 0.120 |
Why?
|
| Antibodies, Bacterial | 5 | 2019 | 1470 | 0.120 |
Why?
|
| Epitopes | 12 | 1998 | 2571 | 0.120 |
Why?
|
| DNA Fingerprinting | 1 | 1994 | 112 | 0.120 |
Why?
|
| Gene Amplification | 1 | 1998 | 1063 | 0.120 |
Why?
|
| Genes | 4 | 1987 | 1893 | 0.120 |
Why?
|
| Immunization | 6 | 2008 | 1256 | 0.120 |
Why?
|
| Mice, SCID | 6 | 2009 | 2717 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 547 | 0.120 |
Why?
|
| Cluster Analysis | 3 | 2017 | 2715 | 0.120 |
Why?
|
| Protozoan Proteins | 2 | 1997 | 827 | 0.120 |
Why?
|
| Child | 16 | 2019 | 77708 | 0.120 |
Why?
|
| Oxygen Consumption | 4 | 1984 | 1868 | 0.110 |
Why?
|
| Interleukin-1beta | 1 | 2019 | 972 | 0.110 |
Why?
|
| Mice, Inbred C3H | 6 | 2005 | 964 | 0.110 |
Why?
|
| Cosmids | 6 | 1998 | 107 | 0.110 |
Why?
|
| Cell Wall | 4 | 1990 | 422 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 1991 | 2540 | 0.110 |
Why?
|
| Molecular Weight | 13 | 1999 | 2255 | 0.110 |
Why?
|
| HIV Infections | 4 | 2020 | 16715 | 0.110 |
Why?
|
| Virulence Factors | 2 | 2009 | 509 | 0.110 |
Why?
|
| Gene Expression Regulation | 7 | 2004 | 12073 | 0.110 |
Why?
|
| Capsid | 1 | 1995 | 437 | 0.110 |
Why?
|
| Laboratory Infection | 1 | 2012 | 7 | 0.110 |
Why?
|
| Biohazard Release | 1 | 2012 | 9 | 0.110 |
Why?
|
| Aerosols | 4 | 2009 | 625 | 0.110 |
Why?
|
| Gene Expression | 12 | 2005 | 7798 | 0.110 |
Why?
|
| Transformation, Bacterial | 2 | 1989 | 78 | 0.110 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2017 | 459 | 0.110 |
Why?
|
| Colony Count, Microbial | 7 | 2009 | 331 | 0.110 |
Why?
|
| Cyclic AMP | 7 | 1984 | 1472 | 0.110 |
Why?
|
| Interleukin-2 | 9 | 1996 | 1904 | 0.110 |
Why?
|
| Health Expenditures | 1 | 2005 | 2349 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 1584 | 0.110 |
Why?
|
| Cholecalciferol | 1 | 2017 | 535 | 0.110 |
Why?
|
| Toll-Like Receptors | 6 | 2006 | 593 | 0.110 |
Why?
|
| Cell Migration Inhibition | 9 | 1979 | 96 | 0.110 |
Why?
|
| Infant | 11 | 2017 | 35134 | 0.110 |
Why?
|
| Vitamin D | 4 | 2017 | 3224 | 0.100 |
Why?
|
| Tetradecanoylphorbol Acetate | 6 | 1993 | 821 | 0.100 |
Why?
|
| Disease Models, Animal | 9 | 2017 | 18034 | 0.100 |
Why?
|
| Heat-Shock Proteins | 7 | 1999 | 822 | 0.100 |
Why?
|
| Medically Uninsured | 3 | 1997 | 853 | 0.100 |
Why?
|
| Antigenic Variation | 1 | 2012 | 125 | 0.100 |
Why?
|
| DNA, Recombinant | 3 | 1987 | 476 | 0.100 |
Why?
|
| Security Measures | 1 | 2012 | 77 | 0.100 |
Why?
|
| Recombinant Proteins | 10 | 2019 | 6621 | 0.100 |
Why?
|
| Nitrogen Oxides | 1 | 1992 | 129 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 1999 | 2513 | 0.100 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2012 | 121 | 0.100 |
Why?
|
| Dietary Proteins | 1 | 1996 | 963 | 0.100 |
Why?
|
| Lipoproteins | 4 | 2004 | 878 | 0.100 |
Why?
|
| Immunoglobulin Fc Fragments | 5 | 1981 | 279 | 0.100 |
Why?
|
| Gene Regulatory Networks | 2 | 2018 | 1708 | 0.100 |
Why?
|
| Skin | 7 | 2021 | 4371 | 0.100 |
Why?
|
| Adjuvants, Immunologic | 7 | 1997 | 1000 | 0.100 |
Why?
|
| Interferon-beta | 1 | 2013 | 324 | 0.100 |
Why?
|
| Blood Bactericidal Activity | 2 | 2006 | 126 | 0.100 |
Why?
|
| Clinical Trials as Topic | 8 | 2013 | 7914 | 0.100 |
Why?
|
| Communicable Diseases | 1 | 2019 | 880 | 0.100 |
Why?
|
| Disaster Planning | 1 | 2017 | 549 | 0.100 |
Why?
|
| Receptors, Immunologic | 6 | 2022 | 1423 | 0.100 |
Why?
|
| Luminescent Measurements | 1 | 1993 | 405 | 0.100 |
Why?
|
| Receptors, Cell Surface | 5 | 2005 | 2866 | 0.090 |
Why?
|
| Information Dissemination | 1 | 2019 | 1099 | 0.090 |
Why?
|
| HLA-DQ Antigens | 1 | 1991 | 210 | 0.090 |
Why?
|
| Artemisinins | 1 | 2012 | 221 | 0.090 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2005 | 780 | 0.090 |
Why?
|
| Mannans | 2 | 2001 | 63 | 0.090 |
Why?
|
| Mutagenesis | 3 | 2002 | 1264 | 0.090 |
Why?
|
| Bacteria | 2 | 2000 | 2115 | 0.090 |
Why?
|
| Lactones | 1 | 2012 | 329 | 0.090 |
Why?
|
| Encephalomyocarditis virus | 1 | 1989 | 20 | 0.090 |
Why?
|
| Antigens, CD1 | 4 | 2005 | 437 | 0.090 |
Why?
|
| Escherichia coli | 11 | 2001 | 4217 | 0.090 |
Why?
|
| Chaperonin 60 | 4 | 1999 | 103 | 0.090 |
Why?
|
| Africa South of the Sahara | 1 | 2012 | 724 | 0.090 |
Why?
|
| Cytotoxicity Tests, Immunologic | 9 | 1997 | 329 | 0.090 |
Why?
|
| Mycobacterium smegmatis | 4 | 2008 | 122 | 0.090 |
Why?
|
| Cathelicidins | 3 | 2019 | 80 | 0.090 |
Why?
|
| Macrophages, Peritoneal | 3 | 2001 | 251 | 0.090 |
Why?
|
| Private Sector | 1 | 2012 | 392 | 0.090 |
Why?
|
| Antibody-Producing Cells | 7 | 1977 | 143 | 0.090 |
Why?
|
| Influenza Vaccines | 1 | 2017 | 738 | 0.090 |
Why?
|
| Latent Tuberculosis | 1 | 2012 | 225 | 0.090 |
Why?
|
| Antibody Specificity | 5 | 1998 | 1095 | 0.090 |
Why?
|
| Trypanosoma cruzi | 4 | 1983 | 197 | 0.090 |
Why?
|
| Kinetics | 9 | 1997 | 6476 | 0.090 |
Why?
|
| Insufflation | 1 | 2009 | 65 | 0.080 |
Why?
|
| Tuberculosis, Bovine | 2 | 2006 | 9 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 1994 | 1364 | 0.080 |
Why?
|
| Protease Inhibitors | 3 | 1983 | 791 | 0.080 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2004 | 1877 | 0.080 |
Why?
|
| Leishmania mexicana | 3 | 1994 | 31 | 0.080 |
Why?
|
| Listeria monocytogenes | 3 | 2005 | 250 | 0.080 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1990 | 174 | 0.080 |
Why?
|
| Vitamins | 1 | 2017 | 1623 | 0.080 |
Why?
|
| Viral Vaccines | 3 | 2013 | 636 | 0.080 |
Why?
|
| Energy Intake | 1 | 1996 | 2148 | 0.080 |
Why?
|
| Trans-Activators | 3 | 2009 | 2926 | 0.080 |
Why?
|
| Leishmania donovani | 1 | 1989 | 65 | 0.080 |
Why?
|
| Macrophages, Alveolar | 3 | 2006 | 407 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2009 | 12209 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 2026 | 0.080 |
Why?
|
| Leishmaniasis, Cutaneous | 3 | 1994 | 124 | 0.080 |
Why?
|
| Anti-Infective Agents | 2 | 2011 | 974 | 0.080 |
Why?
|
| Nucleoproteins | 2 | 1999 | 115 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 9 | 2003 | 6171 | 0.080 |
Why?
|
| Gene Library | 6 | 1996 | 1074 | 0.080 |
Why?
|
| Plasminogen Activators | 6 | 1986 | 209 | 0.080 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 4 | 2004 | 912 | 0.080 |
Why?
|
| Cytoplasmic Granules | 3 | 2006 | 610 | 0.070 |
Why?
|
| Drug Storage | 1 | 2007 | 51 | 0.070 |
Why?
|
| Protein Kinase C | 2 | 1991 | 1227 | 0.070 |
Why?
|
| Drug Resistance, Viral | 1 | 2012 | 820 | 0.070 |
Why?
|
| Chaperonin 10 | 2 | 1997 | 18 | 0.070 |
Why?
|
| Mice, Knockout | 7 | 2004 | 14561 | 0.070 |
Why?
|
| Desiccation | 1 | 2007 | 71 | 0.070 |
Why?
|
| Mammals | 1 | 2012 | 1143 | 0.070 |
Why?
|
| Female | 41 | 2021 | 380200 | 0.070 |
Why?
|
| Transfection | 6 | 1999 | 5895 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 6 | 1999 | 1475 | 0.070 |
Why?
|
| Patient Compliance | 1 | 1997 | 2685 | 0.070 |
Why?
|
| Genetic Complementation Test | 6 | 2003 | 562 | 0.070 |
Why?
|
| Species Specificity | 9 | 1997 | 2478 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 6489 | 0.070 |
Why?
|
| Catalase | 2 | 2000 | 221 | 0.070 |
Why?
|
| Lysosomes | 5 | 2019 | 893 | 0.070 |
Why?
|
| Transcription, Genetic | 6 | 1999 | 7722 | 0.070 |
Why?
|
| Receptors, Fc | 5 | 1983 | 541 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 4 | 1996 | 973 | 0.070 |
Why?
|
| Recombination, Genetic | 6 | 1997 | 1586 | 0.070 |
Why?
|
| Forecasting | 4 | 2001 | 2951 | 0.070 |
Why?
|
| Hemolytic Plaque Technique | 6 | 1977 | 66 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 3508 | 0.070 |
Why?
|
| Infant, Newborn | 7 | 2017 | 25628 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 3020 | 0.070 |
Why?
|
| Diphosphates | 2 | 1995 | 88 | 0.070 |
Why?
|
| Health Promotion | 2 | 2008 | 2205 | 0.070 |
Why?
|
| Culture Techniques | 10 | 1971 | 554 | 0.060 |
Why?
|
| Cell Division | 9 | 1997 | 4569 | 0.060 |
Why?
|
| Mongolia | 2 | 2017 | 91 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 1998 | 5023 | 0.060 |
Why?
|
| Virus Diseases | 5 | 1983 | 711 | 0.060 |
Why?
|
| Academies and Institutes | 1 | 1987 | 317 | 0.060 |
Why?
|
| Health Services Needs and Demand | 3 | 2000 | 1410 | 0.060 |
Why?
|
| Smoking | 1 | 2022 | 8987 | 0.060 |
Why?
|
| Fever | 1 | 2012 | 1616 | 0.060 |
Why?
|
| Science | 1 | 1988 | 241 | 0.060 |
Why?
|
| HIV Seronegativity | 2 | 1997 | 211 | 0.060 |
Why?
|
| Gene Deletion | 3 | 2011 | 2751 | 0.060 |
Why?
|
| Mutation | 13 | 2012 | 29786 | 0.060 |
Why?
|
| Free Radicals | 2 | 1999 | 237 | 0.060 |
Why?
|
| Aminosalicylic Acid | 1 | 2004 | 21 | 0.060 |
Why?
|
| Signal Transduction | 7 | 2019 | 23406 | 0.060 |
Why?
|
| Lymphotoxin-alpha | 2 | 1975 | 98 | 0.060 |
Why?
|
| Food Services | 1 | 2008 | 192 | 0.060 |
Why?
|
| Antibody Formation | 5 | 1991 | 1402 | 0.060 |
Why?
|
| Microbiology | 1 | 2005 | 72 | 0.060 |
Why?
|
| Concanavalin A | 7 | 1980 | 191 | 0.060 |
Why?
|
| Antigens, CD | 2 | 1995 | 4026 | 0.060 |
Why?
|
| Calcitriol | 1 | 2006 | 297 | 0.060 |
Why?
|
| Cholera | 1 | 2011 | 785 | 0.060 |
Why?
|
| Child, Preschool | 8 | 2017 | 41005 | 0.060 |
Why?
|
| Adolescent | 13 | 2021 | 85784 | 0.060 |
Why?
|
| HLA-DR Antigens | 4 | 1997 | 645 | 0.060 |
Why?
|
| Rhodococcus equi | 1 | 2003 | 16 | 0.060 |
Why?
|
| National Health Programs | 1 | 2007 | 445 | 0.060 |
Why?
|
| Membrane Proteins | 3 | 1998 | 7882 | 0.060 |
Why?
|
| Dietary Supplements | 2 | 2017 | 3296 | 0.060 |
Why?
|
| Investments | 1 | 2005 | 143 | 0.060 |
Why?
|
| Perforin | 3 | 2018 | 168 | 0.060 |
Why?
|
| Disabled Persons | 1 | 1993 | 1212 | 0.060 |
Why?
|
| Disease Susceptibility | 4 | 2006 | 1782 | 0.060 |
Why?
|
| Altruism | 1 | 2005 | 204 | 0.060 |
Why?
|
| Preventive Medicine | 1 | 2005 | 264 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2019 | 4369 | 0.060 |
Why?
|
| Herpes Simplex | 1 | 1987 | 470 | 0.060 |
Why?
|
| Immunologic Memory | 4 | 1998 | 1348 | 0.060 |
Why?
|
| Mexico | 1 | 2005 | 689 | 0.060 |
Why?
|
| Th1 Cells | 2 | 2018 | 1057 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 252 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2002 | 2839 | 0.060 |
Why?
|
| Autoimmune Diseases | 3 | 1993 | 2133 | 0.060 |
Why?
|
| Immunity | 3 | 1977 | 1014 | 0.060 |
Why?
|
| Legislation as Topic | 1 | 2003 | 80 | 0.060 |
Why?
|
| Health Services Accessibility | 3 | 1997 | 5135 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2000 | 985 | 0.050 |
Why?
|
| Immunization, Passive | 5 | 1987 | 623 | 0.050 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 1994 | 769 | 0.050 |
Why?
|
| Chagas Disease | 3 | 1982 | 166 | 0.050 |
Why?
|
| Poverty | 2 | 1993 | 2660 | 0.050 |
Why?
|
| Food | 1 | 2008 | 772 | 0.050 |
Why?
|
| Crosses, Genetic | 2 | 2000 | 791 | 0.050 |
Why?
|
| Phenylcarbamates | 1 | 1982 | 38 | 0.050 |
Why?
|
| Chromosomes, Bacterial | 2 | 1996 | 282 | 0.050 |
Why?
|
| Erythema Nodosum | 2 | 2016 | 30 | 0.050 |
Why?
|
| Mortality | 3 | 2019 | 2864 | 0.050 |
Why?
|
| Up-Regulation | 4 | 2019 | 4222 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 1999 | 4386 | 0.050 |
Why?
|
| Chaperonins | 2 | 1999 | 62 | 0.050 |
Why?
|
| Thymidine | 8 | 1977 | 310 | 0.050 |
Why?
|
| Immune System | 1 | 2008 | 806 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 2 | 1999 | 77 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2008 | 802 | 0.050 |
Why?
|
| DNA Primers | 2 | 1998 | 2891 | 0.050 |
Why?
|
| Hydrogen Peroxide | 4 | 1992 | 730 | 0.050 |
Why?
|
| Helsinki Declaration | 1 | 2001 | 6 | 0.050 |
Why?
|
| Simplexvirus | 2 | 1976 | 803 | 0.050 |
Why?
|
| Chromosome Mapping | 4 | 2000 | 4740 | 0.050 |
Why?
|
| Neutrophils | 3 | 2006 | 3721 | 0.050 |
Why?
|
| Insurance, Health | 2 | 1991 | 2494 | 0.050 |
Why?
|
| Bacterial Infections | 2 | 2019 | 1401 | 0.050 |
Why?
|
| Transformation, Genetic | 3 | 1995 | 192 | 0.050 |
Why?
|
| Interleukin-10 | 4 | 2013 | 1200 | 0.050 |
Why?
|
| Primary Health Care | 2 | 1991 | 4557 | 0.050 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2003 | 157 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 927 | 0.050 |
Why?
|
| Genes, MHC Class II | 2 | 1998 | 457 | 0.050 |
Why?
|
| Cell Membrane Permeability | 2 | 2000 | 590 | 0.050 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2002 | 464 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 504 | 0.050 |
Why?
|
| Control Groups | 1 | 2001 | 105 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2000 | 4479 | 0.050 |
Why?
|
| Viral Proteins | 2 | 1999 | 1900 | 0.050 |
Why?
|
| Fenoprofen | 1 | 1980 | 2 | 0.050 |
Why?
|
| Drosophila Proteins | 2 | 2001 | 1703 | 0.050 |
Why?
|
| Cell Membrane | 7 | 2008 | 3749 | 0.050 |
Why?
|
| Microscopy, Electron | 5 | 2000 | 2646 | 0.050 |
Why?
|
| Immunoglobulin G | 7 | 2006 | 4561 | 0.050 |
Why?
|
| Phenylpropionates | 1 | 1980 | 30 | 0.050 |
Why?
|
| Lymphopenia | 2 | 1999 | 285 | 0.050 |
Why?
|
| Health Care Costs | 2 | 2007 | 3209 | 0.050 |
Why?
|
| RNA, Double-Stranded | 1 | 2001 | 290 | 0.050 |
Why?
|
| Skin Tests | 6 | 1992 | 613 | 0.050 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2013 | 61 | 0.050 |
Why?
|
| Adenosine Triphosphate | 2 | 1999 | 2027 | 0.050 |
Why?
|
| Granzymes | 2 | 2018 | 271 | 0.040 |
Why?
|
| Arginase | 1 | 2000 | 79 | 0.040 |
Why?
|
| Cost Savings | 1 | 2005 | 925 | 0.040 |
Why?
|
| Cell Differentiation | 5 | 2018 | 11486 | 0.040 |
Why?
|
| Alleles | 3 | 2003 | 6933 | 0.040 |
Why?
|
| Suramin | 1 | 1999 | 34 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2012 | 2987 | 0.040 |
Why?
|
| Kanamycin Resistance | 2 | 1989 | 10 | 0.040 |
Why?
|
| Hemolysin Proteins | 1 | 1999 | 113 | 0.040 |
Why?
|
| Sarcoma, Experimental | 5 | 1983 | 128 | 0.040 |
Why?
|
| Male | 34 | 2021 | 350118 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1994 | 798 | 0.040 |
Why?
|
| Genetic Code | 2 | 1990 | 154 | 0.040 |
Why?
|
| Research Design | 2 | 2014 | 5986 | 0.040 |
Why?
|
| Indomethacin | 1 | 1980 | 332 | 0.040 |
Why?
|
| Famous Persons | 1 | 2020 | 108 | 0.040 |
Why?
|
| Osteopetrosis | 1 | 1999 | 43 | 0.040 |
Why?
|
| Complement System Proteins | 3 | 1986 | 795 | 0.040 |
Why?
|
| Political Systems | 1 | 2019 | 23 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 3 | 1991 | 1375 | 0.040 |
Why?
|
| Pyridoxal Phosphate | 1 | 1999 | 127 | 0.040 |
Why?
|
| Operon | 2 | 2005 | 363 | 0.040 |
Why?
|
| Microbial Viability | 2 | 2013 | 234 | 0.040 |
Why?
|
| Purinergic P2 Receptor Antagonists | 1 | 1999 | 71 | 0.040 |
Why?
|
| Lymph Nodes | 9 | 1999 | 3475 | 0.040 |
Why?
|
| Peer Review, Research | 2 | 2005 | 329 | 0.040 |
Why?
|
| Tissue Extracts | 2 | 1977 | 135 | 0.040 |
Why?
|
| Cross Reactions | 5 | 1996 | 841 | 0.040 |
Why?
|
| Ligands | 3 | 2001 | 3282 | 0.040 |
Why?
|
| Mycobacterium lepraemurium | 1 | 2018 | 1 | 0.040 |
Why?
|
| Tritium | 6 | 1974 | 745 | 0.040 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 1999 | 85 | 0.040 |
Why?
|
| Mice, Inbred DBA | 7 | 1983 | 642 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 1982 | 880 | 0.040 |
Why?
|
| Microinjections | 1 | 1999 | 327 | 0.040 |
Why?
|
| Cell Compartmentation | 1 | 1999 | 402 | 0.040 |
Why?
|
| Zidovudine | 1 | 2001 | 620 | 0.040 |
Why?
|
| Parasitic Diseases | 1 | 1979 | 75 | 0.040 |
Why?
|
| B-Cell Activating Factor | 1 | 2019 | 119 | 0.040 |
Why?
|
| Multiprotein Complexes | 1 | 2005 | 1120 | 0.040 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2018 | 57 | 0.040 |
Why?
|
| Oxidation-Reduction | 4 | 1990 | 2184 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2007 | 2488 | 0.040 |
Why?
|
| Ascitic Fluid | 2 | 1976 | 192 | 0.040 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1980 | 156 | 0.040 |
Why?
|
| Potassium | 1 | 2003 | 1336 | 0.040 |
Why?
|
| Candida albicans | 1 | 2001 | 394 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 1999 | 6314 | 0.040 |
Why?
|
| Lymphoid Tissue | 3 | 2006 | 455 | 0.040 |
Why?
|
| Pantothenic Acid | 2 | 2011 | 18 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 1312 | 0.040 |
Why?
|
| Pregnancy | 1 | 2020 | 29144 | 0.040 |
Why?
|
| Ethical Review | 1 | 1998 | 26 | 0.040 |
Why?
|
| Indians, South American | 1 | 1997 | 36 | 0.040 |
Why?
|
| Diaminopimelic Acid | 2 | 1994 | 6 | 0.040 |
Why?
|
| Propiophenones | 1 | 1997 | 30 | 0.040 |
Why?
|
| Epidermis | 2 | 2019 | 528 | 0.040 |
Why?
|
| Cattle | 7 | 2006 | 3922 | 0.040 |
Why?
|
| Students | 1 | 2008 | 1651 | 0.040 |
Why?
|
| Placebos | 3 | 1998 | 1676 | 0.040 |
Why?
|
| Motivation | 1 | 2008 | 1971 | 0.040 |
Why?
|
| RNA, Ribosomal | 1 | 2019 | 246 | 0.040 |
Why?
|
| Codes of Ethics | 1 | 1998 | 62 | 0.040 |
Why?
|
| Cell Extracts | 2 | 1977 | 138 | 0.040 |
Why?
|
| Binding, Competitive | 4 | 1988 | 1157 | 0.040 |
Why?
|
| Mycobacterium marinum | 1 | 2017 | 26 | 0.040 |
Why?
|
| Permeability | 1 | 1999 | 738 | 0.040 |
Why?
|
| Models, Biological | 5 | 2011 | 9584 | 0.040 |
Why?
|
| Sheep | 6 | 1981 | 1437 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 1999 | 446 | 0.040 |
Why?
|
| Folic Acid | 1 | 2004 | 1300 | 0.040 |
Why?
|
| Receptors, Calcitriol | 2 | 2013 | 348 | 0.040 |
Why?
|
| Newcastle disease virus | 3 | 1972 | 23 | 0.040 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 2 | 1989 | 27 | 0.040 |
Why?
|
| Tuberculosis, Pleural | 2 | 1994 | 12 | 0.040 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2018 | 79 | 0.040 |
Why?
|
| Cytoplasm | 2 | 1999 | 1536 | 0.040 |
Why?
|
| Cross Protection | 1 | 2017 | 24 | 0.040 |
Why?
|
| Haptens | 4 | 1977 | 166 | 0.040 |
Why?
|
| Animal Structures | 2 | 2009 | 23 | 0.040 |
Why?
|
| Clonal Anergy | 1 | 1997 | 169 | 0.040 |
Why?
|
| Public Health Administration | 1 | 2019 | 240 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 4751 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 712 | 0.040 |
Why?
|
| Keratinocytes | 1 | 2021 | 799 | 0.040 |
Why?
|
| Biological Transport | 3 | 2005 | 2120 | 0.040 |
Why?
|
| United Nations | 1 | 1998 | 165 | 0.040 |
Why?
|
| Genetic Variation | 7 | 1994 | 6542 | 0.040 |
Why?
|
| Ethics | 1 | 1976 | 94 | 0.040 |
Why?
|
| Nitrites | 2 | 1999 | 160 | 0.040 |
Why?
|
| Glucose | 3 | 1984 | 4398 | 0.040 |
Why?
|
| Myelin Sheath | 2 | 2017 | 652 | 0.040 |
Why?
|
| Antilymphocyte Serum | 6 | 1983 | 492 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 1997 | 277 | 0.040 |
Why?
|
| Cell Fusion | 2 | 1993 | 297 | 0.030 |
Why?
|
| Multiple Sclerosis | 3 | 1980 | 3079 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2001 | 587 | 0.030 |
Why?
|
| Mice, Mutant Strains | 2 | 1999 | 1865 | 0.030 |
Why?
|
| Bacteriophages | 2 | 1991 | 356 | 0.030 |
Why?
|
| Moral Obligations | 1 | 1976 | 96 | 0.030 |
Why?
|
| Research Personnel | 1 | 2001 | 573 | 0.030 |
Why?
|
| Poly I-C | 3 | 1987 | 115 | 0.030 |
Why?
|
| Immunoglobulin Idiotypes | 2 | 1989 | 201 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2003 | 3773 | 0.030 |
Why?
|
| Fibroblasts | 4 | 2021 | 4162 | 0.030 |
Why?
|
| Larva | 1 | 2017 | 519 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2017 | 10252 | 0.030 |
Why?
|
| Sequence Alignment | 4 | 2009 | 2256 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 1999 | 673 | 0.030 |
Why?
|
| Costs and Cost Analysis | 2 | 1998 | 1680 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2019 | 591 | 0.030 |
Why?
|
| Rifampin | 1 | 1997 | 315 | 0.030 |
Why?
|
| Armadillos | 3 | 1992 | 7 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 3 | 1995 | 1085 | 0.030 |
Why?
|
| Chromatography, Gel | 5 | 1979 | 668 | 0.030 |
Why?
|
| Immunity, Mucosal | 1 | 1999 | 490 | 0.030 |
Why?
|
| Adult | 15 | 2021 | 214056 | 0.030 |
Why?
|
| Luciferases | 2 | 1997 | 733 | 0.030 |
Why?
|
| Encephalitis, Viral | 1 | 1995 | 55 | 0.030 |
Why?
|
| Sputum | 1 | 2017 | 476 | 0.030 |
Why?
|
| omega-N-Methylarginine | 1 | 1995 | 111 | 0.030 |
Why?
|
| Ribosomes | 1 | 1998 | 500 | 0.030 |
Why?
|
| Vaccines, Combined | 1 | 1995 | 69 | 0.030 |
Why?
|
| Time Factors | 10 | 2008 | 40077 | 0.030 |
Why?
|
| Blotting, Southern | 3 | 1991 | 803 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2005 | 1956 | 0.030 |
Why?
|
| Bronchi | 1 | 1999 | 840 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 708 | 0.030 |
Why?
|
| Leishmania braziliensis | 1 | 1994 | 15 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2005 | 17445 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2000 | 1375 | 0.030 |
Why?
|
| Fibrinolysin | 3 | 1986 | 131 | 0.030 |
Why?
|
| Government Agencies | 1 | 1995 | 156 | 0.030 |
Why?
|
| Ovalbumin | 1 | 1996 | 719 | 0.030 |
Why?
|
| Tuberculosis, Meningeal | 1 | 1975 | 45 | 0.030 |
Why?
|
| Lipids | 2 | 2022 | 3307 | 0.030 |
Why?
|
| RNA Viruses | 2 | 1979 | 124 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2003 | 5451 | 0.030 |
Why?
|
| Aspartate Kinase | 1 | 1994 | 1 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 598 | 0.030 |
Why?
|
| Aspartate-Semialdehyde Dehydrogenase | 1 | 1994 | 4 | 0.030 |
Why?
|
| Antiporters | 1 | 1996 | 277 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2009 | 3914 | 0.030 |
Why?
|
| Resource Allocation | 1 | 1976 | 341 | 0.030 |
Why?
|
| Nitrogen Dioxide | 2 | 1999 | 490 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 844 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 10943 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2001 | 1405 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2001 | 1184 | 0.030 |
Why?
|
| Bacillus anthracis | 1 | 1994 | 123 | 0.030 |
Why?
|
| Politics | 1 | 2020 | 791 | 0.030 |
Why?
|
| Double-Blind Method | 4 | 2017 | 12025 | 0.030 |
Why?
|
| Reactive Oxygen Species | 2 | 1999 | 2076 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 1996 | 257 | 0.030 |
Why?
|
| Incidence | 3 | 2019 | 20950 | 0.030 |
Why?
|
| Superantigens | 1 | 1994 | 129 | 0.030 |
Why?
|
| Leishmania major | 1 | 1993 | 57 | 0.030 |
Why?
|
| Genes, MHC Class I | 1 | 1994 | 258 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 1996 | 315 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2001 | 1320 | 0.030 |
Why?
|
| Protein Biosynthesis | 2 | 1989 | 2126 | 0.030 |
Why?
|
| Interleukin-15 | 1 | 2014 | 184 | 0.030 |
Why?
|
| Growth Inhibitors | 2 | 2006 | 385 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 1998 | 1677 | 0.030 |
Why?
|
| Goals | 1 | 2019 | 707 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1996 | 560 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1997 | 880 | 0.030 |
Why?
|
| Rabbits | 8 | 1981 | 4894 | 0.030 |
Why?
|
| beta-Defensins | 1 | 2013 | 57 | 0.030 |
Why?
|
| B-Lymphocytes | 3 | 2000 | 4666 | 0.030 |
Why?
|
| Antibodies, Viral | 7 | 1997 | 3177 | 0.030 |
Why?
|
| Leukocytes | 2 | 1980 | 2045 | 0.030 |
Why?
|
| Myelin Proteins | 2 | 1986 | 215 | 0.030 |
Why?
|
| Blotting, Western | 5 | 2005 | 5181 | 0.030 |
Why?
|
| Lysogeny | 2 | 1992 | 67 | 0.030 |
Why?
|
| Optic Neuritis | 1 | 1975 | 166 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 1999 | 1530 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1995 | 595 | 0.030 |
Why?
|
| Inflammation | 6 | 2022 | 10636 | 0.030 |
Why?
|
| Extracellular Space | 2 | 2006 | 595 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 2 | 2005 | 1602 | 0.030 |
Why?
|
| Hybridomas | 2 | 1996 | 452 | 0.030 |
Why?
|
| Peroxidases | 1 | 1992 | 138 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2005 | 2789 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2000 | 7182 | 0.030 |
Why?
|
| Health Resources | 1 | 1998 | 911 | 0.030 |
Why?
|
| Universities | 2 | 2008 | 956 | 0.030 |
Why?
|
| Freund's Adjuvant | 4 | 1977 | 139 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1993 | 396 | 0.030 |
Why?
|
| New York City | 1 | 1994 | 710 | 0.030 |
Why?
|
| Drug Combinations | 1 | 1997 | 1958 | 0.030 |
Why?
|
| Binding Sites, Antibody | 3 | 1983 | 349 | 0.030 |
Why?
|
| Neuroglia | 1 | 2017 | 928 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 1992 | 104 | 0.030 |
Why?
|
| Muramidase | 3 | 2008 | 174 | 0.030 |
Why?
|
| Primate Diseases | 1 | 2011 | 15 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 4 | 1986 | 518 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 1991 | 7658 | 0.020 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1991 | 115 | 0.020 |
Why?
|
| DNA Replication | 2 | 1989 | 1399 | 0.020 |
Why?
|
| Rodent Diseases | 1 | 2011 | 57 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 1996 | 847 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 4 | 1974 | 363 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1997 | 1462 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 1973 | 406 | 0.020 |
Why?
|
| Socioeconomic Factors | 3 | 1997 | 7785 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 1997 | 956 | 0.020 |
Why?
|
| Oxygen | 2 | 1994 | 4189 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2005 | 4232 | 0.020 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1998 | 1018 | 0.020 |
Why?
|
| Health Status | 2 | 1994 | 4033 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2183 | 0.020 |
Why?
|
| Calcifediol | 1 | 2011 | 166 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 23336 | 0.020 |
Why?
|
| Infection Control | 1 | 1998 | 965 | 0.020 |
Why?
|
| Baltimore | 1 | 1991 | 231 | 0.020 |
Why?
|
| Open Reading Frames | 4 | 1995 | 811 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2004 | 354 | 0.020 |
Why?
|
| Exudates and Transudates | 3 | 1967 | 172 | 0.020 |
Why?
|
| Phenotype | 5 | 1997 | 16367 | 0.020 |
Why?
|
| Biosynthetic Pathways | 1 | 2011 | 137 | 0.020 |
Why?
|
| Europe | 2 | 1998 | 3339 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 1982 | 370 | 0.020 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1995 | 952 | 0.020 |
Why?
|
| Tubercidin | 2 | 1982 | 16 | 0.020 |
Why?
|
| Neoplasms, Experimental | 3 | 1980 | 1276 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 1991 | 216 | 0.020 |
Why?
|
| HLA Antigens | 3 | 1983 | 1382 | 0.020 |
Why?
|
| Methods | 4 | 1988 | 1129 | 0.020 |
Why?
|
| Antibodies | 5 | 1994 | 2460 | 0.020 |
Why?
|
| Cell Movement | 3 | 1970 | 5218 | 0.020 |
Why?
|
| Powders | 1 | 2009 | 80 | 0.020 |
Why?
|
| Physicians, Family | 1 | 1991 | 345 | 0.020 |
Why?
|
| Leadership | 1 | 2019 | 1357 | 0.020 |
Why?
|
| Esterases | 1 | 1989 | 95 | 0.020 |
Why?
|
| Genes, Viral | 1 | 1991 | 718 | 0.020 |
Why?
|
| Hydroxides | 1 | 1989 | 47 | 0.020 |
Why?
|
| Biopsy | 2 | 2019 | 6755 | 0.020 |
Why?
|
| Macaca mulatta | 2 | 2011 | 2377 | 0.020 |
Why?
|
| Yersinia pseudotuberculosis | 1 | 1989 | 27 | 0.020 |
Why?
|
| Bordetella pertussis | 1 | 1989 | 43 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 3873 | 0.020 |
Why?
|
| Cytochrome c Group | 1 | 1989 | 128 | 0.020 |
Why?
|
| Hydroxyl Radical | 1 | 1989 | 78 | 0.020 |
Why?
|
| Immune Sera | 4 | 1983 | 641 | 0.020 |
Why?
|
| Axons | 1 | 2017 | 1685 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1991 | 517 | 0.020 |
Why?
|
| Age Factors | 3 | 1998 | 18373 | 0.020 |
Why?
|
| Haiti | 1 | 2011 | 553 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1989 | 165 | 0.020 |
Why?
|
| Survival Rate | 2 | 2005 | 12788 | 0.020 |
Why?
|
| Mice, Inbred CBA | 3 | 1993 | 448 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1990 | 1801 | 0.020 |
Why?
|
| Autoimmunity | 1 | 1997 | 1350 | 0.020 |
Why?
|
| Health Behavior | 1 | 2000 | 2635 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2001 | 14723 | 0.020 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1988 | 57 | 0.020 |
Why?
|
| Lymphocyte Cooperation | 2 | 2000 | 112 | 0.020 |
Why?
|
| DNA | 6 | 1989 | 7294 | 0.020 |
Why?
|
| Malaria, Falciparum | 1 | 1997 | 1077 | 0.020 |
Why?
|
| Trypanosomiasis | 2 | 1979 | 8 | 0.020 |
Why?
|
| Restriction Mapping | 3 | 1996 | 878 | 0.020 |
Why?
|
| Salmonella | 1 | 1989 | 129 | 0.020 |
Why?
|
| Depression, Chemical | 3 | 1978 | 191 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2016 | 5974 | 0.020 |
Why?
|
| Leukocyte Migration-Inhibitory Factors | 1 | 1968 | 12 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2001 | 534 | 0.020 |
Why?
|
| Pneumonia | 1 | 2000 | 2133 | 0.020 |
Why?
|
| Graft vs Host Reaction | 2 | 1979 | 104 | 0.020 |
Why?
|
| Urban Health | 1 | 1991 | 547 | 0.020 |
Why?
|
| Age Distribution | 1 | 1994 | 2902 | 0.020 |
Why?
|
| Food, Organic | 1 | 2008 | 34 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2000 | 2104 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 1995 | 1322 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 153 | 0.020 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 1998 | 130 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1996 | 4010 | 0.020 |
Why?
|
| Immunoglobulins | 4 | 1980 | 881 | 0.020 |
Why?
|
| Caregivers | 1 | 2019 | 2095 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 1988 | 162 | 0.020 |
Why?
|
| Erythrocytes | 5 | 1981 | 2455 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 1995 | 4805 | 0.020 |
Why?
|
| Middle Aged | 9 | 2021 | 213388 | 0.020 |
Why?
|
| Vinblastine | 4 | 1972 | 502 | 0.020 |
Why?
|
| Humidity | 1 | 2008 | 197 | 0.020 |
Why?
|
| Mitogens | 2 | 1977 | 232 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 1999 | 3690 | 0.020 |
Why?
|
| Peritoneum | 2 | 1967 | 228 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 5749 | 0.020 |
Why?
|
| alpha-Defensins | 1 | 2006 | 28 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1993 | 1341 | 0.020 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2011 | 570 | 0.020 |
Why?
|
| Isoquinolines | 1 | 1988 | 366 | 0.020 |
Why?
|
| South Africa | 2 | 1991 | 1731 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 1989 | 769 | 0.020 |
Why?
|
| Peptidoglycan | 2 | 2004 | 246 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 1987 | 220 | 0.020 |
Why?
|
| Freezing | 1 | 2007 | 303 | 0.020 |
Why?
|
| Rosette Formation | 3 | 1983 | 153 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2009 | 808 | 0.020 |
Why?
|
| X Chromosome | 1 | 1990 | 814 | 0.020 |
Why?
|
| Immunoglobulin E | 2 | 1983 | 1463 | 0.020 |
Why?
|
| Isoantigens | 2 | 1980 | 567 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2010 | 574 | 0.020 |
Why?
|
| Sphingosine | 1 | 1988 | 307 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 1994 | 1456 | 0.020 |
Why?
|
| Steroid Hydroxylases | 1 | 2006 | 96 | 0.020 |
Why?
|
| Minority Groups | 1 | 1993 | 1220 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2008 | 370 | 0.020 |
Why?
|
| Rats | 8 | 1996 | 24252 | 0.020 |
Why?
|
| Zebrafish | 1 | 2017 | 2996 | 0.020 |
Why?
|
| Virus Cultivation | 2 | 1978 | 92 | 0.020 |
Why?
|
| Actins | 1 | 1993 | 2121 | 0.020 |
Why?
|
| Animals, Congenic | 1 | 2005 | 27 | 0.020 |
Why?
|
| Simian immunodeficiency virus | 1 | 2011 | 846 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 1985 | 570 | 0.020 |
Why?
|
| Genomics | 1 | 2001 | 5717 | 0.020 |
Why?
|
| Biological Warfare | 1 | 2005 | 24 | 0.020 |
Why?
|
| Stimulation, Chemical | 2 | 1977 | 326 | 0.020 |
Why?
|
| Binding Sites | 4 | 1977 | 6111 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 667 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 2 | 1996 | 319 | 0.020 |
Why?
|
| Protein Structure, Secondary | 2 | 2000 | 1247 | 0.020 |
Why?
|
| Amino Acids | 2 | 1989 | 1737 | 0.020 |
Why?
|
| Communication | 1 | 2019 | 3750 | 0.020 |
Why?
|
| Chromium Radioisotopes | 2 | 1974 | 36 | 0.020 |
Why?
|
| Prevalence | 1 | 2002 | 15221 | 0.020 |
Why?
|
| Necrosis | 2 | 2005 | 1643 | 0.020 |
Why?
|
| Proteins | 4 | 1973 | 6100 | 0.020 |
Why?
|
| Peptide Hydrolases | 2 | 1978 | 634 | 0.020 |
Why?
|
| Family Practice | 1 | 1988 | 516 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1977 | 2249 | 0.020 |
Why?
|
| Galactans | 1 | 2004 | 31 | 0.020 |
Why?
|
| Hexosephosphates | 1 | 1984 | 26 | 0.020 |
Why?
|
| Molecular Structure | 1 | 1989 | 1899 | 0.020 |
Why?
|
| Picrates | 1 | 1964 | 13 | 0.020 |
Why?
|
| Mitomycins | 1 | 1964 | 47 | 0.020 |
Why?
|
| Acylation | 1 | 2004 | 107 | 0.020 |
Why?
|
| Nervous System | 1 | 1988 | 554 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1993 | 2969 | 0.020 |
Why?
|
| Food Preferences | 1 | 2008 | 399 | 0.020 |
Why?
|
| Folic Acid Antagonists | 1 | 2004 | 84 | 0.010 |
Why?
|
| Nitroblue Tetrazolium | 1 | 1983 | 17 | 0.010 |
Why?
|
| Interferon Inducers | 2 | 1981 | 25 | 0.010 |
Why?
|
| Glucose Oxidase | 1 | 1983 | 19 | 0.010 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2005 | 298 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 1993 | 1637 | 0.010 |
Why?
|
| Stomatitis | 2 | 1979 | 269 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2017 | 3444 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1996 | 3390 | 0.010 |
Why?
|
| Arachidonic Acids | 1 | 1984 | 299 | 0.010 |
Why?
|
| Pharmacology | 1 | 1964 | 103 | 0.010 |
Why?
|
| Actinomycetales Infections | 1 | 2003 | 30 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1964 | 318 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1984 | 313 | 0.010 |
Why?
|
| Receptors, IgG | 2 | 2004 | 582 | 0.010 |
Why?
|
| Family | 1 | 1994 | 3147 | 0.010 |
Why?
|
| Antimetabolites | 1 | 1964 | 125 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 1995 | 11366 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2000 | 2556 | 0.010 |
Why?
|
| Valine | 2 | 1971 | 413 | 0.010 |
Why?
|
| Xanthine Oxidase | 1 | 1983 | 64 | 0.010 |
Why?
|
| Endosomes | 1 | 2006 | 520 | 0.010 |
Why?
|
| Carbon Isotopes | 3 | 1973 | 467 | 0.010 |
Why?
|
| Nucleosides | 1 | 1964 | 138 | 0.010 |
Why?
|
| Naproxen | 1 | 1983 | 99 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 1990 | 2539 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 1984 | 1378 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 1994 | 3084 | 0.010 |
Why?
|
| Neutralization Tests | 2 | 1996 | 758 | 0.010 |
Why?
|
| Membrane Lipids | 1 | 1984 | 249 | 0.010 |
Why?
|
| Respiratory System | 1 | 2006 | 557 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 1983 | 297 | 0.010 |
Why?
|
| Mitomycin | 1 | 1964 | 259 | 0.010 |
Why?
|
| Cytarabine | 2 | 1977 | 692 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 1984 | 434 | 0.010 |
Why?
|
| Coculture Techniques | 2 | 1997 | 1341 | 0.010 |
Why?
|
| Insulin | 1 | 1977 | 6582 | 0.010 |
Why?
|
| Tosyllysine Chloromethyl Ketone | 1 | 1982 | 5 | 0.010 |
Why?
|
| Tosylphenylalanyl Chloromethyl Ketone | 1 | 1982 | 8 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2003 | 291 | 0.010 |
Why?
|
| Nitrobenzoates | 1 | 1982 | 17 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 1998 | 963 | 0.010 |
Why?
|
| Rats, Inbred Lew | 2 | 1981 | 1162 | 0.010 |
Why?
|
| Methionine | 2 | 1995 | 590 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1995 | 5096 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2012 | 5077 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 1998 | 4255 | 0.010 |
Why?
|
| Bacterial Adhesion | 1 | 2003 | 316 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2005 | 589 | 0.010 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2002 | 139 | 0.010 |
Why?
|
| Phosphates | 1 | 2005 | 785 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1984 | 578 | 0.010 |
Why?
|
| Bromine | 1 | 1981 | 23 | 0.010 |
Why?
|
| Transgenes | 1 | 2005 | 1009 | 0.010 |
Why?
|
| Mice, Nude | 3 | 1983 | 3689 | 0.010 |
Why?
|
| Cell Fractionation | 2 | 1990 | 252 | 0.010 |
Why?
|
| HIV Seropositivity | 2 | 1997 | 971 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 2088 | 0.010 |
Why?
|
| Leukocyte Count | 2 | 1985 | 1588 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1984 | 1137 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1987 | 2242 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1993 | 9849 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1995 | 805 | 0.010 |
Why?
|
| Pepstatins | 1 | 1980 | 10 | 0.010 |
Why?
|
| Chromosomes, Human, 16-18 | 1 | 1980 | 32 | 0.010 |
Why?
|
| Oncogenic Viruses | 1 | 1980 | 42 | 0.010 |
Why?
|
| Plasminogen Inactivators | 1 | 1980 | 38 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 565 | 0.010 |
Why?
|
| beta-Galactosidase | 2 | 1992 | 574 | 0.010 |
Why?
|
| Newcastle Disease | 1 | 1980 | 7 | 0.010 |
Why?
|
| Immunochemistry | 1 | 1980 | 124 | 0.010 |
Why?
|
| Immunogenetics | 1 | 1980 | 67 | 0.010 |
Why?
|
| Young Adult | 2 | 2017 | 56434 | 0.010 |
Why?
|
| Carbamates | 1 | 1982 | 196 | 0.010 |
Why?
|
| Phenylalanine | 1 | 1982 | 365 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 1998 | 7281 | 0.010 |
Why?
|
| Immunoglobulin M | 2 | 1997 | 1537 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1994 | 12244 | 0.010 |
Why?
|
| Liposomes | 1 | 1984 | 759 | 0.010 |
Why?
|
| Mast-Cell Sarcoma | 2 | 1983 | 47 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 2 | 2004 | 5868 | 0.010 |
Why?
|
| Isomerism | 1 | 1980 | 201 | 0.010 |
Why?
|
| Principal Component Analysis | 1 | 2003 | 940 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1980 | 441 | 0.010 |
Why?
|
| Aprotinin | 1 | 1980 | 88 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2005 | 2008 | 0.010 |
Why?
|
| Citrulline | 1 | 2000 | 105 | 0.010 |
Why?
|
| Colony-Stimulating Factors | 1 | 1980 | 221 | 0.010 |
Why?
|
| Silicon Dioxide | 1 | 1981 | 213 | 0.010 |
Why?
|
| Calcium | 2 | 1984 | 5755 | 0.010 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2004 | 571 | 0.010 |
Why?
|
| Parasitic Diseases, Animal | 1 | 1979 | 3 | 0.010 |
Why?
|
| Spinal Cord | 2 | 1981 | 1810 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2000 | 683 | 0.010 |
Why?
|
| Horses | 1 | 1980 | 304 | 0.010 |
Why?
|
| HIV | 1 | 1987 | 1604 | 0.010 |
Why?
|
| Nuclear Proteins | 2 | 2005 | 5857 | 0.010 |
Why?
|
| Staining and Labeling | 2 | 1999 | 1101 | 0.010 |
Why?
|
| Trypanosoma | 1 | 1979 | 16 | 0.010 |
Why?
|
| Inhalation Exposure | 1 | 2002 | 443 | 0.010 |
Why?
|
| Quality of Life | 1 | 2001 | 12803 | 0.010 |
Why?
|
| Ion Channels | 1 | 1984 | 1056 | 0.010 |
Why?
|
| Paralysis | 1 | 1981 | 247 | 0.010 |
Why?
|
| Genetic Markers | 2 | 1996 | 2634 | 0.010 |
Why?
|
| Cell Adhesion | 2 | 1979 | 3144 | 0.010 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1979 | 59 | 0.010 |
Why?
|
| Apoptosis | 2 | 2006 | 9726 | 0.010 |
Why?
|
| Aged | 5 | 2021 | 163284 | 0.010 |
Why?
|
| Subacute Sclerosing Panencephalitis | 1 | 1978 | 24 | 0.010 |
Why?
|
| Cell Survival | 2 | 2008 | 5882 | 0.010 |
Why?
|
| Brain | 6 | 1998 | 26386 | 0.010 |
Why?
|
| Granulocytes | 1 | 1981 | 548 | 0.010 |
Why?
|
| Anions | 1 | 1999 | 133 | 0.010 |
Why?
|
| Inclusion Bodies, Viral | 1 | 1978 | 45 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2008 | 2052 | 0.010 |
Why?
|
| Benzoates | 1 | 1980 | 217 | 0.010 |
Why?
|
| Sonication | 1 | 1979 | 83 | 0.010 |
Why?
|
| Logistic Models | 1 | 1993 | 13409 | 0.010 |
Why?
|
| Haplorhini | 1 | 1979 | 552 | 0.010 |
Why?
|
| Tranexamic Acid | 1 | 1980 | 146 | 0.010 |
Why?
|
| Trinitrobenzenes | 1 | 1977 | 46 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1984 | 1608 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 15520 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1979 | 307 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 2204 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1983 | 695 | 0.010 |
Why?
|
| Strontium | 1 | 1997 | 20 | 0.010 |
Why?
|
| Parasites | 1 | 1980 | 163 | 0.010 |
Why?
|
| Piperazines | 1 | 1988 | 2488 | 0.010 |
Why?
|
| Tyrosine | 1 | 1982 | 1462 | 0.010 |
Why?
|
| Marketing of Health Services | 1 | 1998 | 153 | 0.010 |
Why?
|
| Medicaid | 1 | 1991 | 2737 | 0.010 |
Why?
|
| Suppression, Genetic | 1 | 1977 | 196 | 0.010 |
Why?
|
| Peripheral Nerves | 1 | 1981 | 466 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2008 | 3493 | 0.010 |
Why?
|
| Detergents | 2 | 1990 | 230 | 0.010 |
Why?
|
| Rubber | 1 | 1977 | 50 | 0.010 |
Why?
|
| Filariasis | 1 | 1976 | 28 | 0.010 |
Why?
|
| HIV-1 | 1 | 1995 | 6939 | 0.010 |
Why?
|
| Opsonin Proteins | 1 | 1977 | 150 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1983 | 2227 | 0.010 |
Why?
|
| Palatine Tonsil | 1 | 1977 | 193 | 0.010 |
Why?
|
| HeLa Cells | 2 | 1980 | 3130 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 2765 | 0.010 |
Why?
|
| Picryl Chloride | 2 | 1966 | 9 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1980 | 13695 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1997 | 216 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1997 | 256 | 0.010 |
Why?
|
| Phagocytes | 1 | 1978 | 297 | 0.010 |
Why?
|
| Anaphylaxis | 1 | 1964 | 746 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1978 | 567 | 0.010 |
Why?
|
| Schistosomiasis | 1 | 1976 | 62 | 0.010 |
Why?
|
| Antibodies, Protozoan | 1 | 1997 | 253 | 0.010 |
Why?
|
| Dinitrophenols | 1 | 1975 | 57 | 0.010 |
Why?
|
| Eye | 2 | 1977 | 729 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1996 | 222 | 0.010 |
Why?
|
| Liver | 2 | 2006 | 7475 | 0.010 |
Why?
|
| Streptomyces griseus | 1 | 1995 | 6 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1996 | 170 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 429 | 0.010 |
Why?
|
| Phenylbutazone | 1 | 1955 | 8 | 0.010 |
Why?
|
| Anuria | 1 | 1955 | 15 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1976 | 244 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 1678 | 0.010 |
Why?
|
| Social Values | 1 | 1976 | 224 | 0.010 |
Why?
|
| Models, Animal | 1 | 2002 | 2173 | 0.010 |
Why?
|
| Conjugation, Genetic | 1 | 1996 | 126 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2000 | 1730 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1996 | 349 | 0.010 |
Why?
|
| Latin America | 1 | 1976 | 380 | 0.010 |
Why?
|
| gamma-Globulins | 2 | 1966 | 124 | 0.010 |
Why?
|
| Carbohydrate Conformation | 1 | 1995 | 209 | 0.010 |
Why?
|
| Australia | 1 | 1998 | 1167 | 0.010 |
Why?
|
| Quinacrine | 1 | 1994 | 24 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 9735 | 0.010 |
Why?
|
| DNA, Kinetoplast | 1 | 1994 | 12 | 0.010 |
Why?
|
| Emetine | 1 | 1974 | 15 | 0.010 |
Why?
|
| Carbohydrate Sequence | 1 | 1995 | 414 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 5390 | 0.010 |
Why?
|
| Nasopharynx | 1 | 1997 | 379 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 2 | 1978 | 1041 | 0.010 |
Why?
|
| Betaine | 1 | 1975 | 87 | 0.010 |
Why?
|
| Mental Disorders | 1 | 1994 | 6600 | 0.010 |
Why?
|
| Streptodornase and Streptokinase | 2 | 1971 | 8 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1988 | 8319 | 0.010 |
Why?
|
| Africa | 1 | 1976 | 672 | 0.010 |
Why?
|
| Cranial Nerves | 1 | 1975 | 101 | 0.010 |
Why?
|
| Mycobacterium Infections | 1 | 1995 | 119 | 0.010 |
Why?
|
| Phosphatidylinositols | 1 | 1995 | 291 | 0.010 |
Why?
|
| Antibody Affinity | 1 | 1995 | 254 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 4328 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 3203 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 1681 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 2 | 1994 | 3712 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2000 | 1318 | 0.010 |
Why?
|
| DNA, Ribosomal | 1 | 1995 | 290 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1983 | 1790 | 0.010 |
Why?
|
| Decision Making | 1 | 2008 | 3888 | 0.010 |
Why?
|
| Morals | 1 | 1976 | 285 | 0.010 |
Why?
|
| RNA | 1 | 1964 | 2749 | 0.010 |
Why?
|
| Leishmaniasis, Diffuse Cutaneous | 1 | 1993 | 2 | 0.010 |
Why?
|
| Leishmaniasis, Mucocutaneous | 1 | 1993 | 12 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1997 | 1547 | 0.010 |
Why?
|
| Indoles | 1 | 1982 | 1839 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1994 | 378 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 2918 | 0.010 |
Why?
|
| Brazil | 1 | 1997 | 1270 | 0.010 |
Why?
|
| Skin Ulcer | 1 | 1994 | 120 | 0.010 |
Why?
|
| Vaccines, Conjugate | 1 | 1995 | 333 | 0.010 |
Why?
|
| Perissodactyla | 1 | 1972 | 7 | 0.010 |
Why?
|
| Isoelectric Focusing | 1 | 1973 | 181 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1984 | 8437 | 0.010 |
Why?
|
| Enterotoxins | 1 | 1974 | 368 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 427 | 0.010 |
Why?
|
| Burkitt Lymphoma | 1 | 1995 | 327 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 1998 | 1970 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1973 | 344 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1994 | 394 | 0.010 |
Why?
|
| Demography | 1 | 1997 | 1656 | 0.010 |
Why?
|
| Protein Folding | 1 | 1996 | 840 | 0.010 |
Why?
|
| Glutathione | 1 | 1994 | 590 | 0.010 |
Why?
|
| Proteomics | 1 | 2005 | 3638 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1997 | 1880 | 0.010 |
Why?
|
| Lac Operon | 1 | 1992 | 238 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1997 | 1073 | 0.010 |
Why?
|
| Glass | 1 | 1972 | 114 | 0.010 |
Why?
|
| Temperature | 1 | 1978 | 2204 | 0.010 |
Why?
|
| Vaccines, Inactivated | 1 | 1992 | 184 | 0.010 |
Why?
|
| Optic Nerve | 1 | 1975 | 554 | 0.010 |
Why?
|
| Sciatic Nerve | 1 | 1975 | 607 | 0.010 |
Why?
|
| DNA, Circular | 1 | 1991 | 97 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1995 | 995 | 0.010 |
Why?
|
| Acute Disease | 2 | 1979 | 7147 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1994 | 651 | 0.010 |
Why?
|
| Interleukin-5 | 1 | 1991 | 273 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1983 | 2214 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 1996 | 2012 | 0.010 |
Why?
|
| Octoxynol | 1 | 1990 | 77 | 0.010 |
Why?
|
| Cell Separation | 1 | 1977 | 1751 | 0.010 |
Why?
|
| Foot | 1 | 1994 | 527 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1995 | 1526 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 63115 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1994 | 1202 | 0.010 |
Why?
|
| Saliva | 1 | 1995 | 809 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1997 | 1837 | 0.010 |
Why?
|
| NF-kappa B | 1 | 1999 | 2499 | 0.010 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1970 | 87 | 0.010 |
Why?
|
| Leukemia, Experimental | 1 | 1971 | 246 | 0.010 |
Why?
|
| Herpesviridae | 1 | 1971 | 109 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1974 | 692 | 0.010 |
Why?
|
| Candidiasis | 1 | 1973 | 366 | 0.010 |
Why?
|
| Edema | 1 | 1994 | 789 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1995 | 693 | 0.010 |
Why?
|
| Benz(a)Anthracenes | 1 | 1969 | 12 | 0.010 |
Why?
|
| Methylcholanthrene | 1 | 1969 | 29 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1996 | 2726 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1991 | 379 | 0.010 |
Why?
|
| Mice, Inbred A | 2 | 1983 | 248 | 0.010 |
Why?
|
| Inbreeding | 1 | 1969 | 49 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1970 | 240 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1993 | 903 | 0.010 |
Why?
|
| Acrylic Resins | 1 | 1970 | 142 | 0.010 |
Why?
|
| Cell Count | 2 | 1971 | 1856 | 0.010 |
Why?
|
| Autoradiography | 1 | 1970 | 745 | 0.010 |
Why?
|
| Colchicine | 1 | 1970 | 244 | 0.010 |
Why?
|
| Data Collection | 1 | 1998 | 3339 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1994 | 57776 | 0.010 |
Why?
|
| Kanamycin Kinase | 1 | 1988 | 34 | 0.010 |
Why?
|
| Swine | 1 | 1979 | 5918 | 0.010 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 1975 | 957 | 0.010 |
Why?
|
| Viral Load | 1 | 1997 | 3300 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1970 | 330 | 0.010 |
Why?
|
| Transplantation Immunology | 1 | 1971 | 546 | 0.010 |
Why?
|
| Peptides | 1 | 2000 | 4410 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 13285 | 0.000 |
Why?
|
| Income | 1 | 1997 | 1913 | 0.000 |
Why?
|
| Analgesics | 1 | 1955 | 1040 | 0.000 |
Why?
|
| RNA, Viral | 1 | 1977 | 2901 | 0.000 |
Why?
|
| Vibrio cholerae | 1 | 1974 | 807 | 0.000 |
Why?
|
| Culture Media | 1 | 1970 | 909 | 0.000 |
Why?
|
| Chemotaxis | 1 | 1971 | 607 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1996 | 4933 | 0.000 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1991 | 1159 | 0.000 |
Why?
|
| Lectins | 1 | 1970 | 513 | 0.000 |
Why?
|
| Nerve Tissue Proteins | 1 | 1980 | 4464 | 0.000 |
Why?
|
| Phosphotransferases | 1 | 1988 | 308 | 0.000 |
Why?
|
| Solubility | 1 | 1989 | 1088 | 0.000 |
Why?
|
| Serum Albumin | 1 | 1970 | 675 | 0.000 |
Why?
|
| Risk Factors | 1 | 1994 | 72295 | 0.000 |
Why?
|
| Antioxidants | 1 | 1994 | 1659 | 0.000 |
Why?
|
| Population Surveillance | 1 | 1997 | 2616 | 0.000 |
Why?
|
| Capillary Permeability | 1 | 1970 | 798 | 0.000 |
Why?
|
| Peritoneal Cavity | 1 | 1966 | 148 | 0.000 |
Why?
|
| Tetanus Toxoid | 1 | 1986 | 193 | 0.000 |
Why?
|
| Lysophosphatidylcholines | 1 | 1986 | 81 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1971 | 1267 | 0.000 |
Why?
|
| Membranes | 1 | 1966 | 173 | 0.000 |
Why?
|
| Dermatitis, Contact | 1 | 1966 | 129 | 0.000 |
Why?
|
| Phospholipases A | 1 | 1986 | 216 | 0.000 |
Why?
|
| Ion Exchange Resins | 1 | 1964 | 7 | 0.000 |
Why?
|
| Polyethylene Glycols | 1 | 1990 | 1182 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1996 | 8300 | 0.000 |
Why?
|
| Random Allocation | 1 | 1989 | 2428 | 0.000 |
Why?
|
| Papain | 1 | 1964 | 64 | 0.000 |
Why?
|
| Antigens, Neoplasm | 1 | 1972 | 1988 | 0.000 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1964 | 131 | 0.000 |
Why?
|
| Splenectomy | 1 | 1966 | 395 | 0.000 |
Why?
|
| Catalysis | 1 | 1986 | 762 | 0.000 |
Why?
|
| Serum Globulins | 1 | 1983 | 24 | 0.000 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1985 | 573 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1964 | 829 | 0.000 |
Why?
|
| Algorithms | 1 | 2003 | 13882 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1986 | 1799 | 0.000 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1983 | 305 | 0.000 |
Why?
|
| Chemistry, Physical | 1 | 1981 | 156 | 0.000 |
Why?
|
| Antigens, Ly | 1 | 1983 | 291 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1981 | 518 | 0.000 |
Why?
|
| Myelin P0 Protein | 1 | 1981 | 15 | 0.000 |
Why?
|
| Testicular Neoplasms | 1 | 1947 | 806 | 0.000 |
Why?
|
| Spinal Nerve Roots | 1 | 1981 | 121 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1983 | 867 | 0.000 |
Why?
|
| Radiation Chimera | 1 | 1979 | 223 | 0.000 |
Why?
|
| Blood-Brain Barrier | 1 | 1986 | 1019 | 0.000 |
Why?
|
| Sodium | 1 | 1964 | 1622 | 0.000 |
Why?
|
| Models, Theoretical | 1 | 1970 | 3589 | 0.000 |
Why?
|
| Plasminogen | 1 | 1978 | 152 | 0.000 |
Why?
|
| Thorium Dioxide | 1 | 1977 | 20 | 0.000 |
Why?
|
| Graft Rejection | 1 | 1971 | 4397 | 0.000 |
Why?
|
| Protein Binding | 1 | 1970 | 9384 | 0.000 |
Why?
|
| Immunosorbent Techniques | 1 | 1977 | 184 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1989 | 8642 | 0.000 |
Why?
|
| Cats | 1 | 1978 | 1000 | 0.000 |
Why?
|
| Vacuoles | 1 | 1977 | 230 | 0.000 |
Why?
|
| Cholera Toxin | 1 | 1978 | 556 | 0.000 |
Why?
|
| Neurons | 1 | 1975 | 9340 | 0.000 |
Why?
|
| Golgi Apparatus | 1 | 1975 | 410 | 0.000 |
Why?
|
| Ammonium Sulfate | 1 | 1972 | 29 | 0.000 |
Why?
|
| Chromatography | 1 | 1972 | 206 | 0.000 |
Why?
|
| Chemical Precipitation | 1 | 1972 | 179 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1972 | 313 | 0.000 |
Why?
|
| Neoplasms | 2 | 1971 | 21693 | 0.000 |
Why?
|
| Electrophoresis, Disc | 1 | 1971 | 70 | 0.000 |
Why?
|
| Dextrans | 1 | 1972 | 595 | 0.000 |
Why?
|
| Threonine | 1 | 1971 | 279 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 1992 | 39052 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1979 | 2948 | 0.000 |
Why?
|
| Blood Donors | 1 | 1971 | 355 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1983 | 4253 | 0.000 |
Why?
|
| Melanoma | 1 | 1983 | 5511 | 0.000 |
Why?
|
| Neoplasm Proteins | 1 | 1972 | 3706 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1983 | 13104 | 0.000 |
Why?
|